// App-Quantinova.ai

352 : The Effect of Belimumab (BEL) on Kidney Outcomes in SLE: Results of a Large Integrated Analysis

Researchers

Presenter

  • Maria Dall'Era

Principal Investigators

  • Andrea Fava

  • Christine Henning

  • Angela R Jones-Leone

  • Angela S Carroll

  • Julia H N Harris

  • Anne E Hammer

  • Roger A Levy

  • Laurence S Magder

  • Michelle Petri

Medical Centers

  • University of California, Division of Nephrology, San Francisco, USA

  • Johns Hopkins University School of Medicine, Devision of Rheumatology, Baltimore, MD

  • GlaxoSmithKline, Global Medical Affairs, Durham, NC

  • GlaxoSmithKline, Global Medical Affairs, Collegeville, PA

  • GlaxoSmithKline, US Medical Affairs, Research Triangle Park, NC

  • GlaxoSmithKline, Immunology Biostatistics, Brentford, United Kingdom

  • GlaxoSmithKline, Immunology Biostatistics, Collegeville, PA

  • University of Maryland Department of Epidemiology and Public Health, Baltimore, MD

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

Biomarkers

  • N/A

Drug/Treatment

  • Belimumab

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved